Notizia Archives - DelveInsight

Notizia

Recent Pharma News
Notizia

Bluebird declares the price of its gene therapy- ZyntegloBluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for trea...


transthyretin amyloidosis
Idera’s drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly termin...

Idera's dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial carried on adults with ...


transthyretin amyloidosis
Notizia

Arbor Biotechnologies shining with new CRISPR enzyme Arbor Biotechnologies is shining with its new CRISPR enzyme and has successfully bagged USD 15.6 million in series A funding. The company has r...


Notizia
Notizia

Anthera’s Sollpura flops after phase 3 Anthera cut free it’s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared "key choices". Sollpura was out-licensed by...


transthyretin amyloidosis
CRISPR to cure sickle cell; FDA rejected; Stem cells use; Celgene spinoff

Rice University researchers tested CRISPR to cure sickle cell, now preparing for upcoming challenges A team of Researchers led by Rice University has recently tested CRISPR to correct the sickle ce...


transthyretin amyloidosis
Notizia

Key to new Cancer drugs discovered in bacterial genomes Achievement is made by the scientists of The Scripps Research Institute (TSRI) Florida campus who had previously discovered LNM E1 compound ...


transthyretin amyloidosis
Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Ac...

Regeneron/Sanofi’s PD-1 drug candidate will be tested with ISA’s HPV immunotherapy Regeneron and Sanofi’s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma’s human papillomavirus (H...


transthyretin amyloidosis
Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allerg...

Positive Phase 2 data for Roche’s lymphoma ADC Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab has already received breakthrough designation from the USFDA and priority medici...


Notizia
KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s...

KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms Neurocrine Biosciences, Inc. announced new long-term data from the KINECT 4 Phase III open-label study demonstr...


BioGen
Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of th...


Editor's Pick
Bone Metastasis Market: A Debilitating Consequence for Many Tumors

In advanced cancer patients, the most common site for the occurrence of metastasis is c...

Evaluating the Role of Digital Therapeutics as an Alternative to Conventional...

Depression is a mental condition characterized by prolonged series of poor moods, loss ...

Exploring the Market Potential of the Upcoming Therapies for the Myasthenia G...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...

Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...

Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.